Research programme: neurodegenerative disease therapeutics - Neuronascent

Drug Profile

Research programme: neurodegenerative disease therapeutics - Neuronascent

Alternative Names: NNI-362; NNI-370

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuronascent
  • Class Small molecules
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Parkinson's disease

Most Recent Events

  • 24 Jan 2017 Neuronascent has patent protection for several new groups of compounds treating neurological conditions in USA
  • 05 Feb 2015 Neuronascent receives patent allowance for NNI 362 in USA
  • 21 Nov 2013 Clinical candidates are available for licensing as of 19 Nov 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top